证券研究报告 鱼跃医疗 (002223 CH) 海外业务亮眼，各板块恢复正增长 | 华泰研究 | | | 中报点评 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | --- | | 2025 年 | 8 月 | 25 日│中国内地 | 医疗器械 | 目标价(人民币): | 58.85 | 公司 1H25 收入/归母净利润/扣非归母净利润 46.59/12.03/9.14 亿元，同比 +8.2%/+7.4%/-5.2% ； 2Q25 收 入 / 归母净利润 / 扣 非 归 母 净 利 润 22.23/5.78/4.01 亿元，同比+7.1%/+25.4%/-3.0%。1H25 新冠基数影响已 基本消化，各项业务增速均转正，海外业务收入持续快速增长，我们看好后 续核心业务收入增速进一步恢复，维持买入评级。 海外收入快速增长，呼吸制氧板块恢复增长趋势 1H25 公司国内收入 40.26 亿元，同比+5.7%；海外收入 6.07 亿元，同比 +26.6%，海外贡献收入占比达 13.0%，海外业务正逐步成为推动公司业绩 增长的重要动力之一。1H25 公司核心赛道表现不 ...

公 司 报 告 医药 2025年08月25日 鱼跃医疗(002223.SZ) 业绩增长符合预期，血糖AED等业务表现亮眼 强烈推荐( 维持) 公 司 半 年 报 点 评 股价:36.6元 主要数据 | 行业 | 医药 | | --- | --- | | 公司网址 | www.yuwell.com | | 大股东/持股 | 江苏鱼跃科技发展有限公司/24.54% | | 实际控制人 | 吴光明 | | 总股本(百万股) | 1,002 | | 流通A股(百万股) | 940 | | 流通B/H股(百万股) | | | 总市值(亿元) | 367 | | 流通A股市值(亿元) | 344 | | 每股净资产(元) | 13.27 | | 资产负债率(%) | 18.8 | 行情走势图 证券分析师 叶寅 投资咨询资格编号 S1060514100001 BOT335 YEYIN757@pingan.com.cn 倪亦道 投资咨询资格编号 S1060518070001 事项： 公司25H1实现营业收入46.59亿元，yoy+8.16%，实现归母净利润12.03亿 元，yoy+7.37%，实现扣非归母净利润9.14亿元， ...

Core Viewpoint - The medical sector is experiencing significant activity, with the largest medical ETF in A-shares (512170) showing a 2% increase, nearing last year's peak, indicating strong investor confidence in the medical market [1][3]. Group 1: ETF Performance - The medical ETF (512170) reached a peak increase of 2%, with a trading volume exceeding 700 million yuan on the morning of August 25 [1]. - The latest scale of the ETF is 27.94 billion yuan, maintaining a leading position among similar ETFs [1]. - On the previous trading day, the ETF saw a net subscription of 98.54 million yuan, reflecting positive market sentiment towards the medical sector [1]. Group 2: Market Dynamics - Major stocks within the ETF, such as Meihua Medical and Lepu Medical, surged over 15%, while Wu Electric Physiology and other companies experienced declines [1][3]. - The ETF passively tracks the CSI Medical Index, with top-weighted stocks including Mindray Medical, United Imaging Healthcare, and Aier Eye Hospital [3]. Group 3: Policy and Innovation - The National Medical Products Administration announced support for companies to conduct global clinical trials simultaneously, aiming to shorten the drug approval process [3]. - A recent investment cooperation exchange meeting in Shenzhen focused on supporting the development of pharmaceuticals and medical devices [4]. - The establishment of a domestic medical technology innovation zone at the Medical Expo highlighted breakthroughs in domestic technology, with companies like Mindray and Weigao showcasing advanced diagnostic equipment [5]. Group 4: Industry Outlook - CITIC Securities noted that the performance and valuation of the medical device sector are gradually recovering, with recent procurement policies being optimized [5]. - The medical device industry is expected to benefit from policy easing, procurement clearance, and strategic transformations, with internationalization, technological innovation, and mergers and acquisitions becoming key growth paths [5].

Core Viewpoint - Yuyue Medical is strategically focusing on digitalization and wearable technology, with significant growth in home respiratory devices and overseas sales, indicating a robust market expansion and product innovation strategy. Digitalization and Wearable Technology - The company is integrating digital technology with medical devices, focusing on continuous glucose monitoring (CGM) systems that encompass hardware, software, and algorithms for comprehensive digital application [2] - Yuyue Medical plans to launch AI-powered wearable medical devices aimed at health management, covering various health monitoring scenarios [2][4] - The integration of the Yuyue AIAgent app with the existing health management platform is intended to create a unified health management ecosystem [2] Home Respiratory Devices - Home respiratory device sales grew over 40% year-on-year, driven by the launch of an upgraded sleep apnea machine and enhanced brand strength facilitating import substitution [2][3] - The company is expanding its market presence in Europe and Thailand, with ongoing registration efforts and improved distribution channels [3] Continuous Glucose Monitoring (CGM) - New CGM products, Anytime4 and Anytime5, have received positive user feedback, contributing to the brand's growing market presence [3] - AI technology is being incorporated into CGM product development to enhance service capabilities and user experience [3] Home Health Monitoring Solutions - The home health monitoring segment saw a 15.22% growth, with electronic blood pressure monitors leading the category due to strong user trust and product performance [4] Overseas Business Development - Yuyue Medical achieved 607 million yuan in overseas sales, a 26.63% increase, with respiratory therapy products leading the export growth [5] - The Southeast Asian market, particularly Thailand, has shown rapid growth, with plans to replicate successful strategies in other regions [5][6] Emergency Solutions and Growth Drivers - The "Emergency Solutions and Others" segment reported a 30.54% revenue increase, with emergency product growth outpacing the overall segment [6][7] - Future growth drivers include an expanding product matrix, increasing brand influence, and a significant opportunity for AED penetration in the domestic market [7]

Core Insights - Yuyue Medical (002223.SZ) reported a revenue of 4.659 billion yuan for the first half of 2025, marking an 8.16% year-on-year increase, with a net profit of 1.203 billion yuan, up 7.37% year-on-year [1] - The company is focusing on the integration of AI and healthcare, aiming to create a comprehensive ecosystem that combines hardware, AI, and services [1][2] - Yuyue Medical is actively expanding its global presence and enhancing its product ecosystem through digitalization and wearable technology [1][5] Financial Performance - Revenue for the respiratory therapy solutions segment reached 1.674 billion yuan, a 1.93% increase year-on-year, with home respiratory machine products growing over 40% [2] - Blood glucose management and POCT solutions generated 674 million yuan, reflecting a 20% year-on-year growth, with the latest CGM product achieving significant sales [2] - Home health testing solutions achieved 1.014 billion yuan in revenue, up 15.22% year-on-year, driven by strong performance in electronic blood pressure monitors and infrared thermometers [2] Strategic Directions - The company is committed to three strategic directions: globalization, digitalization, and wearable technology, with a focus on long-term growth and global vision [2][4] - Yuyue Medical is enhancing its product offerings through the integration of AI technology, aiming for a fully IoT-enabled product line [3][4] - The company has invested 295 million yuan in R&D, a 9.44% increase year-on-year, to support its innovation and product development efforts [3] Global Expansion - Yuyue Medical has successfully established a localized sales model in Thailand, achieving rapid business growth since the establishment of its subsidiary in 2021 [5] - The company aims to replicate its Thailand model in other regions, focusing on local culture and operational support [5] - In the first half of the year, overseas revenue reached 607 million yuan, a 26.63% increase year-on-year, supported by 85 international registrations [6] Industry Positioning - Yuyue Medical is recognized as a leader in the home medical device sector in China, continuously enhancing its brand image and technical advantages [1][6] - The company actively participates in international exhibitions and academic exchanges to showcase its innovations and expand its global influence [6] - The internationalization of the medical device industry is seen as an unstoppable trend, with Yuyue Medical leveraging its technological advancements and cost advantages to enhance its global market presence [6]

Core Insights - Pension funds have increased their presence in the secondary market, appearing in the top ten circulating shareholders of 75 stocks by the end of Q2, with 22 new entries and 23 increased holdings [1][2] - The total shareholding of pension accounts reached 679 million shares, with a total market value of 14.592 billion yuan [1] - The most significant holdings include Haiyou Development and Mingtai Aluminum, with shareholdings of 52.1022 million shares and 45.0001 million shares, respectively [1][2] Group 1: Pension Fund Holdings - By the end of Q2, pension accounts held the largest number of shares in Haiyou Development, ranking as the fifth-largest circulating shareholder [1] - The pension fund's largest holding by market value includes 41 stocks with a market value exceeding 100 million yuan, such as Chunfeng Power, Lanxiao Technology, and Yuyue Medical [1][2] - The highest shareholding ratio among pension accounts is in Lanxiao Technology, with a holding of 20.8 million shares, accounting for 6.78% of circulating shares [1][2] Group 2: Performance and Sector Distribution - The pension fund's stock holdings are primarily concentrated in the main board (49 stocks), with 7 in the Sci-Tech Innovation Board and 19 in the Growth Enterprise Market [2] - The pension fund's investments are mainly in the basic chemical and pharmaceutical industries, with 11 and 9 stocks, respectively [2] - Among the stocks held, 50 companies reported net profit growth in their semi-annual reports, with the highest growth seen in Rongzhi Rixin, achieving a net profit of 14.2355 million yuan, a year-on-year increase of 2063.42% [2]

2025 年上半年鱼跃医疗的整体业绩表现如何？ 2025 年上半年，鱼跃医疗实现营业总收入 46.59 亿元，同比增长 8.16%；归 母净利润 12.03 亿元，同比增长 7.37%；扣非后归母净利润 9.14 亿元，同比 下降 5.22%。经营活动产生的现金流量净额 11.67 亿元，同比增长 15.13%。公司销售毛利率为 50.37%，同比上升 0.37 个百分点。期间费用为 12.22 亿元，同比增加 23.85%，其中研发费用 2.95 亿元，同比增长 9.44%。 公司在全球化、数字化和可穿戴化战略方面有哪些进展？ 鱼跃医疗坚定践行全球化、数字化和可穿戴化三大战略。在全球化方面，公司 持续推动海内外渠道建设及属地化布局，以泰国子公司为标杆，加速海外核心 区域子公司的建设，带动当地业务迅速发展。报告期内，公司实现外销收入 6.07 亿元，同比增长 26.63%，占总营收比例提升至 13.03%。在数字化和可 急救解决方案板块营收 1.36 亿元，同比增长 30.5%。国内外业务占比 基本为 1:1，国内增速略高于海外。未来增长驱动力来自 AED 产品矩阵 完善、注册证书落地和普美康品牌力增强。 公 ...

Group 1: Digital and Wearable Technology - The company is integrating digital technology with medical devices, focusing on digitalization and wearability as core directions [3] - The CGM product combines hardware, software, and algorithms for comprehensive digital application, with ongoing development of new monitoring products [3] - AI smart wearable medical devices are being developed to enhance health management, covering various health monitoring scenarios [3][4] Group 2: Home Respiratory Devices - Home respiratory device sales grew over 40% year-on-year, driven by the launch of a third-generation sleep apnea machine [4] - The company is focusing on increasing market penetration in domestic and international markets, with a low current penetration rate in China [4] - The company aims to accelerate import substitution with quieter and smarter new products [4] Group 3: Continuous Glucose Monitoring (CGM) - The CGM products Anytime 4 and Anytime 5 have received positive user feedback and are enhancing brand influence [5] - AI technology is being integrated into CGM product development to improve service capabilities and user experience [5] Group 4: Home Health Monitoring Solutions - Home health monitoring solutions achieved a 15.22% growth, with electronic blood pressure monitors showing double-digit growth [6] - The company maintains a high market share and gross margin through quality assurance and brand strength [6] Group 5: Wearable Device Advantages - The company leverages deep technical expertise and continuous innovation in the medical device field to support wearable device development [7] - Emphasis is placed on health management and user habit analysis to enhance product differentiation and market competitiveness [7] Group 6: Overseas Business Development - The company achieved foreign sales revenue of 607 million yuan, a year-on-year increase of 26.63%, accounting for 13.03% of total revenue [8] - Southeast Asia, particularly Thailand, has shown rapid growth, with plans to replicate successful models in other regions [8][9] - The company is expanding its product offerings in overseas markets, focusing on respiratory and glucose monitoring products [9] Group 7: Emergency Solutions Growth - The emergency solutions segment generated 136 million yuan, a year-on-year increase of 30.54%, with emergency products growing faster than the overall segment [10] - Future growth drivers include a rich product matrix and increasing brand influence in professional events [10]

Core Insights - The recent disclosure of semi-annual reports by A-share listed companies reveals significant movements among institutional investors, particularly pension funds [1] Group 1: Institutional Investment Trends - In the second quarter, pension funds entered the top ten circulating shareholder lists of over 20 stocks [1] - The total market value of stocks newly held by pension funds, with a market value exceeding 100 million yuan, includes 11 companies: Hongfa Technology, Satellite Chemical, Shengyi Electronics, Yuyue Medical, Jereh Group, Angel Yeast, Taineng Technology, Huace Testing, Hisense Home Appliances, Gongda Electronics, and Cambridge Technology [1] - Additionally, pension funds also entered the top ten circulating shareholder lists of companies such as Weichai Heavy Machinery, Huafeng Aluminum, Luxi Chemical, Jingneng Electric Power, Nova Star Cloud, Fuda Co., Tianqin Equipment, Shanhaishan, Gaoxingxing, Jiuzhitang, Doli Technology, Zhongce Rubber, Weifeng Electronics, and Baolijia [1]

Investment Rating - The report maintains an "Increase" rating for the medical device sector, with specific recommendations for companies like 恒瑞医药 (Hengrui Medicine), 鱼跃医疗 (Yuyue Medical), 迈瑞医疗 (Mindray), and 联影医疗 (United Imaging) [4][5]. Core Viewpoints - The report emphasizes structural investment opportunities in the medical device sector due to policy optimization and recovering demand. It suggests that supportive policies from the National Medical Products Administration (NMPA) will drive rapid development in high-end imaging equipment, surgical robots, brain-computer interfaces, and AI+medical fields. Companies with strong R&D capabilities and high brand recognition in these segments are expected to benefit [2][23]. - Since the second half of 2024, there has been a significant improvement in demand for medical devices, particularly in the equipment sector. The report anticipates a gradual recovery in the industry, with growth rates being revised upwards as procurement demand translates into financial results for listed companies [2][24]. Summary by Sections Market Review - The A-share medical biotechnology index rose by 1.05%, underperforming the CSI 300 index by 3.13 percentage points and the ChiNext index by 3.47 percentage points, ranking 29th among 31 sub-industries. The H-share Hang Seng Medical Health Index increased by 0.93%, outperforming the Hang Seng Index by 0.48 percentage points [1][16]. Company Updates - Recent clinical application updates include 康诺亚's AZD0901 injection and 科伦博泰's HBM9378 injection, both of which have new clinical applications. 恒瑞医药's HRS-7058 capsule has a new IND application, while 恩华药业's NH600001 emulsion injection has a new NDA application [30][31]. Recommendations - The report recommends increasing exposure to the medical device sector, highlighting undervalued companies in Hong Kong such as 微创医疗 (MicroPort), 微创机器人-B (MicroPort Robotics), and 威高股份 (Weigao Group). It also suggests focusing on stable growth consumer medical device companies like 鱼跃医疗, 三诺生物 (Sinocare), and 美好医疗 (Meihua Medical) [2][24]. Financial Forecasts - The report provides earnings per share (EPS) forecasts for key companies, with 恒瑞医药 projected at 1.36 CNY for 2025, 鱼跃医疗 at 2.32 CNY, 迈瑞医疗 at 10.62 CNY, and 联影医疗 at 2.39 CNY. The price-to-earnings (PE) ratios for these companies are also provided, indicating potential investment value [4]. Industry Demand - The report notes a significant recovery in demand for medical devices, with the market size for publicly tendered medical equipment showing a year-on-year increase of 58.33% in the first half of 2025, following a decline of 38.10% in the first half of 2024 [24]. Policy Environment - The report highlights recent policy changes aimed at supporting high-end medical device innovation, which are expected to lead to a more rational competitive environment and gradual price recovery in the sector [23][24]. Conclusion - Overall, the report presents a positive outlook for the medical device sector, driven by policy support and recovering demand, with specific investment recommendations for leading companies in the field [2][4].